Juvenescence appoints a new CEO for its Epigenetic Division and Souvien Bio Ltd
Juvenescence - 11-Jun-2020Goal is to develop drugs that target epigenetic mechanisms associated with neurodegeneration
Join the club for FREE to access the whole archive and other member benefits.
Biotech company of the life sciences company Juvenescence is focused on developing new therapies to modulate essential epigenetic mechanisms associated with neurodegeneration
Souvien is founded on the pioneering research of Professor Li-Huei Tsai, the director of The Picower Institute for Learning and Memory at MIT, and Associate Professor Stephen Haggarty, the director of the Chemical Neurobiology Laboratory at Harvard Medical School/Massachusetts General Hospital, on the epigenetic underpinnings of neurodegeneration.
Professor Tsai said: “We have collected a substantial body of data implicating a critical epigenetic regulator of cellular aging in neurodegeneration. We are delighted to establish this new venture with Juvenescence and their experienced team of proven drug developers.”
“I’m excited to join forces with Juvenescence and their partners as we develop unprecedented therapies from the bench into the clinic,” said Dr. Haggarty.
See also: Juvenescence - Developing therapies against different aging related diseases.
Details last updated 05-Jul-2020
Goal is to develop drugs that target epigenetic mechanisms associated with neurodegeneration